Our findings imply that EV-delivered miR-208b represents a promising target for the improvement of MI treatment, and targeting the miR-208b/CDKN1A pathway may function as a novel therapeutic approach in CVD. The gene discussed is CDKN1A; the disease is myocardial infarction.